A Safety and Dose Finding Trial of C-Tb, When Given to Adult Patients Recently Diagnosed With Active Tuberculosis

Tuberculosis Clinical Trial

— TESEC-02  

Official title:

A Safety and Dose Finding Trial of the Diagnostic Test C-Tb, When Given Intradermally by the Mantoux Technique to Adult Patients Recently Diagnosed With Active TB

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01033929
• Other study ID #: TESEC-02
• Secondary ID: 2009-012984-33
• Status: Completed
• Phase: Phase 1
• First received: December 16, 2009
• Last updated: January 18, 2013
• Start date: January 2010
• Est. completion date: November 2010

Study information

• Verified date: January 2013
• Source: Statens Serum Institut
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The primary objective is to assess the safety of two doses of C-Tb (0.01 and 0.1 µg/0.1 mL) when administered intradermally by the Mantoux technique to patients in the acute phase of treatment against active TB. The secondary objectives are to assess the immune response of two doses (0.01 and 0.1 µg/0.1 mL) of C-Tb from the size of induration and to assess the safety of unpreserved C-Tb and C-Tb preserved with 0.5% phenol (local reactions).

Description:

This clinical trial is a single centre phase Ib open dose adjustment study with respect to the dose of C-Tb combined with a double blind randomised, split-body comparison of unpreserved C-Tb and C-Tb preserved with 0.5% phenol (each patient receives the unpreserved version in one arm and the preserved version in the other arm).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: November 2010
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

The patient:

1. Has signed an informed consent

2. Is willing and likely to comply with the trial procedures

3. Has been diagnosed with active TB and has been in treatment = 60 days at the time of inclusion

• has 1 documented positive sputum smear microscopy result

• has positive culture

• has a positive PCR result for tuberculosis

• has a compatible clinical picture of TB with the intention to treat

4. Has a positive T-spot assay or a QuantiFERON®-TB Gold In Tube test

5. Is prepared to grant authorized persons access to their medical records

Exclusion Criteria:

The patient:

1. Has been in treatment with a product which is likely to modify the immune response within 3 months prior to the day of inclusion (e.g., immunoglobulin, systemic corticosteroids, methotrexate, azathioprine, cyclosporine or blood products)

2. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. BCG, MMR, yellow fever, oral typhoid vaccines)

3. Has a known congenital or acquired immune deficiency

4. Has a disease affecting the lymphoid organs (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis)

5. Is infected with HIV

6. Has severe scarring, burn, rash, eczema, psoriasis, or any other skin disease at or near the injection sites

7. Has a condition where blood drawings pose more than minimal risk for the patient, such as haemophilia, other coagulation disorders, or significantly impaired venous access

8. Is actively participating in another clinical trial

9. Is pregnant according to urine pregnancy test at inclusion

10. Has a condition which in the opinion of the investigator is not suitable for participation in the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Biological:
• rdESAT-6 + rCFP-10 (C-Tb)
rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.

Locations

Country	Name	City	State
United Kingdom	St George's University of London	London	London SW17 0RE

Sponsors (1)

Lead Sponsor	Collaborator
Statens Serum Institut

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Local and systemic adverse reactions at the injection sites within 28 days after application of the tests (0.01/0.1 µg C-Tb).		Within 28 days after the injections	Yes
Secondary	Immune response of 2 doses (0.01 and 0.1 µg/0.1 mL) of C-Tb from the size of induration; the safety of unpreserved C-Tb and C-Tb preserved with 0.5% phenol and the pain associated with the injection of unpreserved C-Tb and preserved C-Tb		Within 28 days after the injections	Yes